EMPACT-MI
a streamlined, multicentre, randomised, double-blind superiority study to evaluate efficacy and safety of empagliflozin 10 mg once daily compared to placebo, in patients hospitalised for acute myocardial infarction with high risk of heart failure and mortality
- Stage
- klaar
- Medicine
- Empagliflozin
- Population
- ASCVD
- Phase
- III
- First Patient In
- 23 June 2021
- Last Patient In
- 22 February 2023
- Last Patient Last Visit
- 31 October 2023
National Lead
dr. P van der Meer
Cardioloog
Study Director
dr. T.J. Römer
Cardioloog
Office Contact
